Mesoblast (NASDAQ:MESO) Stock Price Down 8.5% – Here’s What Happened

Mesoblast Limited (NASDAQ:MESO)’s stock price fell 8.5% on Monday . The stock traded as low as $14.44 and last traded at $14.50. 166,270 shares traded hands during trading, a decline of 21% from the average session volume of 211,650 shares. The stock had previously closed at $15.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Mesoblast Price Performance

The business’s 50-day moving average price is $17.86 and its 200 day moving average price is $16.91. The company has a market capitalization of $1.87 billion, a P/E ratio of -16.51 and a beta of 2.15. The company has a quick ratio of 1.77, a current ratio of 1.99 and a debt-to-equity ratio of 0.11.

Mesoblast (NASDAQ:MESO) last posted its earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $25.67 million for the quarter. Analysts anticipate that Mesoblast Limited will post -0.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Mesoblast

A number of institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Mesoblast during the 4th quarter valued at about $34,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Mesoblast by 30.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after buying an additional 558 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Mesoblast by 55.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after acquiring an additional 1,012 shares during the last quarter. JFS Wealth Advisors LLC bought a new stake in shares of Mesoblast during the 3rd quarter worth $54,000. Finally, Farther Finance Advisors LLC purchased a new position in Mesoblast in the third quarter worth $58,000. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.